Anti-CTLA-4 blockade with ipilimumab was the first treatment to prolong overall survival (OS) in patients with advanced melanoma (Figure 2), yet checkpoint therapy against PD-1 has proven more effective in several other types of cancer [43]. Here, PDCD1 is linked to cancer.